INTRODUCTION
Male breast cancer is an uncommon disease, accounting for less than 1% of malignancies in men, and less than 1% of all breast cancers. Approximately 300 men in the UK are diagnosed with the disease each year¹. Incidence appears to be increasing, which may be a reflection of increasing longevity in the population or the rising rates of obesity in developed countries².
The bimodal age distribution seen in female breast cancer is absent in males, where peak incidence occurs around the age of 70³.The aetiology is not fully understood, although, as in females, hormonal, environmental and genetic factors have been implicated. Hormonal imbalance occurring endogenously secondary to testicular abnormalities increases risk. Additionally, exogenous oestrogens such as in men treated for prostate cancer increases risk, and individuals with Klinefelter's syndrome (47XXY) have a 20-50 times higher risk of developing the condition 4 . Obesity, a common cause of hyperoestrogenism, has been implicated. Gynaecomastia, physiological male breast tissue, does not increase risk 5 . Genetic factors appear to play more of a role in males than in females with approximately 10% of men with breast cancer carrying BRCA2 mutations, while mutations in BRCA1 are exceedingly rare 6 . Recently, the CHEK2 1100delC variant has been found to give a 10-fold risk of male breast cancer independent of BRCA1 or BRCA2 7 .
Male breast cancer presents at a later age and often more advanced stage with larger tumour size and more frequent nodal involvement than in females. As a consequence, overall survival rates are lower for men and have not improved over the last number of years as female outcomes have³.
Treatment guidelines are largely based on existing knowledge from treatment of females as no randomised controlled trials exist to support a specific therapeutic approach. Retrospective studies have not suggested different treatment algorithms should be employed. As with females, treatment involves surgery, with simple mastectomy followed by either sentinel node biopsy or formal axillary clearance being the procedure of choice. As the condition is predominantly hormone-receptor-positive, hormonal therapy is an essential component of treatment 8 
PATIENTS AND METHODS
A database has been maintained for all breast cancer patients diagnosed in our unit since 1993. Patients diagnosed with the condition from 1994 to 2009 were identified and data was collected from the database and retrospective chart review with review of histopathological reports. Patients were followed to cause of death by reference to the database and this was confirmed using Northern Ireland Electronic Care Record (NIECR). All patients with the condition were included for analysis. No patients were excluded. Information collated included patient demographics, tumour pathology, treatment and outcomes. Due to the fact that not all tumours were examined for hormone receptor status in the midnineties, no information was available on human epidermal growth factor (HER-2) status for 16 tumours. Furthermore 7 tumours were not examined for oestrogen receptor (ER) status and 15 tumours not examined for progesterone receptor (PR) status. Unfortunately, no histological grading was stated on the histopathology reports for 2 tumours. All other data was complete. Unit policy has been to treat male breast cancer on the basis of tumour biology, staging and comorbidity as would be best practice with females. Data were collected on Microsoft Excel (Microsoft Corp, Redmond, WA, USA) and then analysed using SPSS (Version 12, SPSS Inc, Chicago, Il, USA). Age, tumour size and Nottingham Prognostic Index (NPI) were expressed as mean and standard deviation. (Table 3) .
RESULTS

DISCUSSION
This retrospective case series is limited by its small size as is often the case with male breast cancer studies worldwide. Our results show similar demographics to other studies, with a high mean age at diagnosis and a comparable frequency of histopathological type of disease. The rate of nodal involvement is lower than other studies published 3, 5, 11 .
Surgery has been the mainstay of our treatment protocols, with the most commonly performed operation being mastectomy and axillary node clearance. In recent years' sentinel node biopsy has been more common, and as patients were selected carefully based on tumour size, no patients have required further axillary surgery. We have performed wide local excision with nipple preservation in 2 patients, one of which required mastectomy due to close proximity of surgical margins.
All patients were started on Tamoxifen and completed a duration of treatment of 5 years with the exception of one patient who required cessation of therapy due to deep vein thrombosis.
Although not all patients were tested for hormone receptor status in the mid-nineties, our results suggest that all the patients in our unit tested for hormone receptor status had oestrogen receptor positive breast cancer. Oestrogen receptor status was however unknown in 7 cases. HER2 status was negative when tested however results were unavailable for 16 tumours. No patients received Trastuzumab.
Retrospective studies investigating the benefit of radiotherapy have suggested better local control with radiotherapy and improved overall survival for stage 1 disease but no association with improved cause-specific survival 12 .
The role for adjuvant chemotherapy is not well established 13 .
Eleven patients had radiotherapy and no patient, either in the radiotherapy or no radiotherapy groups developed local or regional recurrence. One patient who did have radiotherapy developed distant metastases. It is impossible to ascertain if this means our selection process for radiotherapy is effective and accurate or if there is no difference resulting from radiotherapy.
Only one patient developed systemic disease and had chemotherapy and so we are unable comment on its benefit. Other studies have reported an uptake of chemotherapy in the region of 33%
13
. Despite only one patient in this study receiving chemotherapy, outcomes have been excellent with regard to disease free survival. This may suggest chemotherapy is not particularly useful unless systemic disease exists.
Historically, overall survival and disease free survival for male breast cancer have been lower than that of female breast cancer 3 . Contributory causes include a lack of awareness in the population, later stage at diagnosis and reduced uptake of adjuvant treatment. In more recent years overall and disease specific survival have been shown to comparable with females when matched for age and stage 14 . Our study shows tenyear disease free survival (80%) in our unit is comparable to other published studies 5, 14 . Only one patient has died from their breast cancer. Ten-year overall survival is consistent with other reported studies at 22%, showing that the high age at diagnosis is the most important factors in determining outcome. In particular, comorbidity and development of second cancers appears to be more important than in females.
CONCLUSIONS
In this small retrospective case series, treatment of male breast cancer has been based on principles similar to those for females, namely pathology, tumour biology, and patient co-morbidity. It is likely that age at diagnosis and medical co-morbidity were the most important prognostic factors in determining ten-year overall survival. Mastectomy and Tamoxifen would appear to be the most effective treatments. We suggest that males should be treated proactively and no differently from females.
Outcomes for male breast cancer would appear to be consistent with that described in the literature 5, 14 . However, given the fact that numbers are limited, the question of whether the prognosis for breast cancer is worse in males than in the female population remains unanswered. It is difficult, if not impossible to carry out adequately powered randomised controlled trials as they would necessarily involve multiple centres and a long study period. Due to speed of progress in the treatment of female breast cancer, where large randomised controlled trials are feasible, it may be most appropriate to concentrate on providing males with comparable treatment to females, specifically best treatment practices for post-menopausal breast cancer. Future research must be at national or international level to ensure the most effective treatments are implemented for these patients. An ongoing international retrospective male breast cancer programme with prospective study by The European Organisation for Research and Treatment of Cancer (EORTC) may provide additional understanding of optimal treatment approaches and long term outcomes for male breast cancer patients.
